Novel therapies are clearly needed for gliomas, and the combination of oncolytic vectors with chemotherapy possesses a significant hope for the treatment of this malignancy. In addition, combination with chemotherapy allows for lower virus doses to achieve anticancer effect, thus resulting in lower undesirable toxicities due to viral proteins. In this work, we sought to determine whether combination of an oncolytic adenovirus ICOVIR-5, with RAD001 or temozolomide (TMZ) could result in enhanced anti-glioma effect in vivo. We assessed the in vitro cytotoxic effect and replication properties of ICOVIR-5 in combination with RAD001 or TMZ in U87 MG glioma cell line by MTT and TCID 50 , respectively. Our data showed that in vitro treatment with RAD001 or TMZ not only interfered with adenovirus replication but, in addition, enhanced its oncolytic properties. To evaluate the in vivo anticancer effect, athymic mice bearing glioma xenografts (5 Â 10 5 U87 MG cells/animal) received a single intratumoral injection of ICOVIR-5 (10 7 PFU/animal). RAD001 was given as a regimen of 5 mg/kg 5 days per week until the end of the experiment and TMZ was administered for 5 days at 7.5 mg/kg/mice. Of significance, combination of ICOVIR-5 with RAD001 or TMZ showed a potent antiglioma effect in vivo, resulting in a dramatic extension of the median animal survival and in 20-40% animals becoming free of disease beyond 90 days.
Introduction
The therapeutic management of malignant gliomas remains unsatisfactory. The prognosis of patients diagnosed with glioblastoma multiforme (GBM) is grim and the median survival ranges from 9 to 12 months despite maximum treatment. 1 Thus, new effective therapeutic approaches are greatly needed. One of the approaches to design novel, rational and effective treatments directed against the molecular defects of these tumors involves the use of oncolytic adenoviruses. However, improvements in both potency and selectivity are still required to obtain therapeutic effect in clinical trials. We have previously constructed and characterized the oncolytic effect of the tumor-selective adenovirus ICOVIR-5. ICOVIR-5 has enhanced tropism through integrin infection (RGD-4C modification of the fiber HI loop), 2 tumor selectivity (Delta-24 mutation in the Rb-binding CR2 region of E1A), 3 and decreased E1A-mediated toxicity (insertion of two E2F1-responsive element promoter preceded by an insulator upstream of the E1A coding sequence). We showed that ICOVIR-5 is a highly selective vector and at the same time, it displays a robust cell-killing potential in vitro and in vivo. 4 Combination of oncolytic vectors with chemotherapy presents a significant hope for the treatment of this malignancy. Mathematical modeling shows that the balance between the rate of tumor-cell growth and virus spread is a critical determinant of the outcome of oncolytic virus infection. 5 Whether chemotherapy acts directly on tumor cells by inducing cell arrest or cell death or indirectly by blocking tumor angiogenesis or inhibiting the host immunoresponse, the resulting delay in tumor growth may provide the oncolytic virus with a wider window of opportunity to overcome the challenge imposed by the growth kinetics of the tumor. Several preclinical studies have showed that RAD001 induces potent anti-cancer effect with negligible toxicity. 6 Furthermore, RAD001's immunosuppressive and antiangiogenesis effects could benefit adenoviral-based therapies by maintaining viral spread intratumorally because of a decrease in the production of neutralizing antibodies. 7 Temozolomide (TMZ) is the first agent in 20 years approved by the FDA to treat malignant glioma and has become the standard treatment for the majority of gliomas. 8 The current study was designed to ascertain whether the combination therapy of the oncolytic adenovirus ICOVIR-5 with RAD001 or TMZ could result in enhanced anti-glioma effect in vivo. Our results showed that combination treatment of ICOVIR-5 with either drug led to a significant increase in the anti-cancer effect in vitro and in vivo glioma xenograft model.
Materials and methods

Cell lines and culture conditions
The glioma cell line U87 MG was obtained from the American Type Culture Collection. Cell lines were maintained in Dulbecco's modified Eagles/F12 medium (DMEM/F12) (1:1, v/v) supplemented with 10% fetal bovine serum in a humidified atmosphere containing 5% CO 2 at 371C.
Adenovirus construction and infection ICOVIR-5 inactivated by UV light (UVi) and mockinfected cells (that is by DMEM/F12) were used as controls. ICOVIR-5 was constructed as described previously 4 with the following modification; a Kozak sequence was inserted before E1A. To insert the Kozak sequence before E1A, a KpnI fragment from pShuttle-DM-E2F-Delta-24 containing the E2F promoter and E1A was subcloned into pGEM-3Z (Promega, Madison, WI), and this plasmid was used to replace the E1A translation start site using oligonucleotides with the Kozak sequence. The Kpn1 fragment containing the E2F-E1A modified with the Kozak sequence was returned to pShuttle-DM-E2F-D24 to obtain pShuttle-DM-E2F-KD24. Finally, pShuttle-DM-E2F-D24 was recombined by homologous recombination with pVK503 that contains complete Ad5 genome with RGD-modified fiber.
Cell viability assay U87 MG cells were seeded at a density of 5 Â 10 3 cells/well in 96-well plates and on the next day, cells were infected with Delta-24-RGD or at multiplicity of infections (MOIs) of 0.1 and 1 at 371C for 30 min. In addition, cells were treated with RAD001 or TMZ at a concentration ranging from 10 nM to 100 mM or from 1 nM to 1000 mM, respectively. MTT experiments were performed to quantify cell viability, as described previously.
2 Dose-response curves were analyzed using CalcuSyn software (Biosoft, Cambridge, UK). CalcuSyn fits the dose-response curves to Chou-Talalay lines. 9 Dm is the median-effect dose (the dose causing 50% of cells to be affected, that is 50% survival). Chemotherapy and virus were then added in combinations, with each dose in each experiment plated in triplicate and each experiment performed three times. After fitting the combined dose-response curve from a single representative experiment to a Chou-Talalay line, Chou-Talalay combination indices (CIs) were calculated. Levels of interaction are defined as follows: CI41.3 indicates antagonism, CI between 1.1 and 1.3 indicates moderate antagonism, CI between 0.9 and 1.1 indicates additivity, CI between 0.8 and 0.9 indicates slight synergy, CI between 0.6 and 0.8 indicates moderate synergy, CI between 0.4 and 0.6 indicates synergy, and CIo0.4 indicates strong synergy. 10 
Viral replication assays
We seeded U87 MG glioma cells at 5 Â 10 4 cells/well in six-well plates and 20 h later infected with the indicated adenovirus at an MOI of 1. Three days after infection, we scraped the cells into culture medium and lysed them with three cycles of freezing and thawing. We used the tissue culture infection dose replication assay (TCID 50 method) to determine the final viral titration. Briefly, the cell lysates were clarified by centrifugation and the supernatants were serially diluted in medium for infecting A549 cells in 96-well plates. We analyzed the cells for CPE 10 days after infection. Final titers were determined as plaque forming units (PFU), using the validation method developed by Quantum Biotechnology (Carlsbad, CA).
SYBR-Green real-time quantitative PCR analysis of gene expression
Total RNA was isolated and reverse-transcribed using M-MLV reverse transcriptase (Sigma Chemical Corporation, St Louis, MO) and quantitative-PCR analysis was performed on a chromo 4 sequence-detection system (Bio-Rad, Hercules, CA) using a SYBR-green PCR master mix (Applied Biosystems, Foster City, CA), and specific primers for E1A (forward: 5 0 -TCGGGCGTCTC AGGATAGC-3 0 ; reverse: 5 0 -GAGGATGAAGAGGGT CCTGTGT-3 0 ) and fiber (forward: 5 0 -CGGCCTCCGA ACGGTACT-3 0 ; reverse: 5 0 -TCTTGCGCGCTTCATC TTG-3 0 ) and the house-keeping gene b-actin (forward:
. 11 The cycling conditions for PCR were as follows: 10 min at 951C for 1 cycle; 15 s at 951C, and 1 min at 601C for 40 cycles. To determine relative gene expression, the comparative threshold cycle (CT) method was used. For the animal studies, total RNA from three different specimens was isolated and assayed in triplicate.
Animal studies
For the survival animal studies, nude (nu/nu) mice were obtained from the breeding facility at the University of Texas MD Anderson Cancer Center. U87 MG human glioma cells (5 Â 10 5 ) were engrafted into the caudate nucleus of athymic mice using a previously described guide-screw system. 2 On day 3 after the implantation of tumor cells, animals were treated with one single intratumoral injection of ICOVIR-5 (3 Â 10 7 PFU/mouse) or PBS. RAD001 (5 mg/kg/day) was administered by oral gavage, and TMZ (7.5 mg/kg/day for 5 days) was administered intraperitoneally. Both treatments were started on day 3 after the implantation of tumor cells. Animals showing general or local symptoms of toxicity were killed. Surviving animals were killed 90 days after tumor implantation. Brains were then removed, fixed in 4% formaldehyde for 24 h at room temperature, and embedded in paraffin. Hematoxylin-and eosin-stained sections were evaluated for evidence of tumor, necrosis and viral nuclear inclusions. All animal studies were performed in the veterinary facilities of the University of Texas MD Anderson Cancer Center in accordance with institutional, state and federal laws and ethical guidelines for experimental animal care.
Immunohistochemical analysis
To detect adenoviral E1A and hexon proteins in the tumor xenografts, paraffin-embedded sections of the mouse tumors were deparaffinized and rehydrated with xylene and ethanol, following conventional procedures. These sections were then treated with either goat antihexon antibody (diluted 1:200; Chemicon) or goat anti-E1A (diluted 1:200; Santa Cruz) at 401C overnight. For immunohistochemical staining, Vectastain ABC kits (Vector Laboratories, Burligame, CA) were used according to the manufacturer's instructions.
Statistical analysis
For the in vitro experiments, statistical analyses were performed using a two-tailed Student's t-test. Data are expressed as mean and standard deviation. The in vivo cytopathic effect of ICOVIR-5 on human glioma xenografts was assessed by plotting survival curves according to the Kaplan-Meier method. Survival in different treatment groups was compared using the log-rank test. Pair-wise comparisons of the difference in the proportion of surviving mice were performed with the Fisher's exact test.
Results and discussion
First, we assessed the cytotoxic potential of RAD001 or TMZ alone or in combination with ICOVIR-5 in vitro in U87 MG cells. Interestingly, treatment with either drug in combination with ICOVIR-5 showed enhanced antitumoral effect, thereby reducing the dosage needed to achieve the median-effect dose (dose causing 50% of survival) (Figure 1a) . Moreover, assessment of the interaction between the virus and the drug showed a reduction of at least 10-fold on each dose for the combined treatment. Interestingly, CIs in U87 MG cells demonstrated synergy in nearly all combinations (that is ICOVIR-5 1 MOI plus RAD001 10 nM presented a CI ¼ 0.152; ICOVIR-5 0.1 MOI plus TMZ 100 nM presented a CI ¼ 0.238). It was possible that the drugs, RAD001 and TMZ might have decreased viral titers in infected cells by alkylating newly synthesized viral DNA or through other mechanism. Importantly, TCID 50 analyses proved that the addition of neither RAD001 nor TMZ impaired or decreased viral titers (Figure 1b) . Specifically, there were not significant differences (P40.05) in the resulting viral titers after treatment with ICOVIR-5 alone (5 Â 10 7 PFU/ml) or in combination with RAD001 (1 Â 10 7 PFU/ml) or TMZ (4.3 Â 10 7 PFU/ ml) in U87 MG glioma cells. Viral replication was further confirmed by the detection of fiber expression at the mRNA and protein level (Figure 1c ). Since the combination treatment with ICOVIR-5 and drugs showed a significant antitumoral effect in vitro, we wanted to assess the potential therapeutic relevance of these regimens in vivo. To test our hypothesis, we designed an experiment where we delivered a single injection of ICOVIR-5 (3 Â 10 7 PFU). The antitumoral efficacy of ICOVIR-5 in combination with RAD001 or TMZ was evaluated in the U87 MG intracraneal tumor model. The median survival of the control mice (injected with PBS or UV-inactivated ICOVIR-5) was 30.5 days (95% confidence interval ¼ 30-32 days). The median survival times for animals treated with a single agent was 49 days (95% confidence interval ¼ 45-52 days) for animals treated with RAD001 (5 mg/kg/day), 35.5 days (95% confidence interval ¼ 33-37 days) for those treated with TMZ (7.5 mg/kg/ per day, for 5 consecutive days), and 35 days (95% confidence interval ¼ 34-39 days) for animals treated with ICOVIR-5 (a single dose of 3 Â 10 7 PFU/ mice). Importantly, animals treated with the combination of virus and drugs showed a significant increase in the median survival time. Thus, animals receiving ICOVIR-5 and RAD001 survived an average of 72.5 days (95% confidence interval ¼ 51 days to NA) and mice treated with ICOVIR-5 and TMZ survived 62 days on average (95% confidence interval ¼ 39 days to NA) (Figures 1d  and e) . Furthermore, ICOVIR-5 in combination with RAD001 or TMZ generated long-term survivors. Thus, 20% of animal treated with ICOVIR and RAD001 survived more than 90 days without neurological deficits. The long-term-survivor percentage was even higher in animals treated with ICOVIR and TMZ and hence we observed that 40% of mice in this treatment group survived 90 days without symptoms of disease (Figures 1d  and e) . Examination of the brains of animals treated with RAD001 or TMZ revealed a large area of necrosis in the center of the tumor and scattered smaller areas of tumor necrosis. Immunohistochemical staining for E1A and hexon protein was positive in the brains of mice treated with either ICOVIR-5 as a single agent or in combination with one of the two drugs, indicating that chemotherapy did not prevent adenoviral infection and replication (Figure 1f ). In agreement with these data, the levels of E1A or fiber mRNA were very similar in tumors treated with ICOVIR-5 alone (45 and 37.5-fold, respectively) or in combination with RAD001 (43 and 37.3-folds, respectively) or TMZ (40 and 33.5-fold, respectively). Collectively, our data indicate that chemotherapy significantly enhances the anti-tumor effect of ICOVIR-5. In the case of the combination of oncolytic viruses and TMZ, a TMZ-mediated upregulation of DNA repair genes has been hypothesized as a main mechanism enhance viral replication in HSV. 12 However, adenovirus needs to inactivate DNA repair mechanism to replicate efficiently and thus, potentially enhancing the cytotoxicity exerted by agents such as TMZ. We have addressed this question by assessing the DNA damage in samples treated with TMZ alone or in combination with ICOVIR-5 by Figure 1) . Our data showed that samples treated with combination of virus and TMZ exhibited significantly greater DNA damage than those treated with the drug alone. Because the success of oncolytic adenoviral therapies depends on its efficacy versus toxicity profile, the combination of oncolytic adenovirus with chemotherapy will provide a major advantage, which is the possibility of reducing the dosages to achieve therapeutic effect. Reducing the dosage will avoid hampering clinical trials by the relatively elevated doses of oncolytic viruses administered in animal models to achieve an anticancer effect and by the even higher doses required in humans to approximate an animal bioequivalent dose. Such elevated doses of injected viral proteins may also lead to undesirable toxicities and are also very difficult to produce in a biotechnological setting. We have further shown that therapy with oncolytic viruses in combination with RAD001 or TMZ is more effective than treatment with either agent alone. One explanation for these results is probably based on the immunosuppressant effect of chemotherapy 13 that should favor adenoviral replication in vivo. In addition, RAD001 antiangiogenic effects have been postulated as a possible rationale for the enhancement of the oncolytic effect. 7 It is possible that RAD001 and TMZ are promoting oncolysis through different mechanisms. Thus, we cannot rule out the possibility that combination of these three agents would further increase the effectiveness of ICOVIR-5.
In this work, we showed that the anti-cancer effect of ICOVIR-5 was drastically enhanced by the combination with either RAD001 or TMZ. Our data constitute strong evidence that conventional and experimental therapy of gliomas enhance the anti-glioma effect of ICOVIR-5 and deserve further clinical testing.
